(Credit:AP Graphics)

(CBS/AP) Hepatitis C deaths are on the rise, according to a new report from the Centers for Disease Control and Prevention. the report found baby boomers are especially at risk because they account for two-thirds of all hepatitis C cases.

The worrisome news has prompted health officials to wonder whether anyone born between 1945 and 1965 should get a blood test for hepatitis C, because many of these boomers may have had the disease for decades without even realizing it.

“One of every 33 baby boomers are living with hepatitis C infection,” says Dr. John Ward, the CDC’s hepatitis chief. “Most people will be surprised, because it’s a silent epidemic.”

Some baby boomers may not think they’re at risk because sharing a needle while injecting illegal drugs is the biggest risk factor for becoming infected with this blood-borne virus. But before 1992, when widespread testing of the blood supply began, hepatitis C commonly was spread through blood transfusions. Plus, a one-time experiment with drugs way back when could have been enough.

“Asking someone about a risk that happened 20 to 30 years ago is a lot to ask,” says Ward. That’s why officials are seeking a new strategy.

About 3.2 million Americans are estimated to have chronic hepatitis C, but at least half of them may not know it. the virus, which affects 170 million people worldwide, can gradually scar the liver and lead to cirrhosis, liver failure, or liver cancer. it is a leading cause of liver transplants.

For the CDC’s study, published in the Feb. 21 issue of the Annals of Internal Medicine, researchers analyzed a decade of death records and found an increase in death rates from hepatitis C. in fact, in 2007 there were 15,000 deaths related to hepatitis C, higher than previous estimates – and surpassing the nearly 13,000 deaths caused by the better-known AIDS virus. perhaps more surprising, three-fourths of the hepatitis deaths occurred in the middle-aged, people 45 to 64-years old.

“Mortality will continue to grow for the next 10 to 15 years at least unless we do something different” to find and treat the silent sufferers, Ward says.

Current CDC guidelines recommend testing people known to be at high risk, and until last summer there wasn’t much enthusiasm even for that step: the reasons are the year-long, two-drug treatment promised to cure only 40 percent of people; treatment was so grueling that many patients refused to try it and treatment could cost up to $30,000.

Two new drugs – Vertex Pharmaceuticals’ telaprevir and Merck & Co.’s boceprevir – are starting to change that pessimism. Research suggests adding one of them to standard therapy can boost cure rates as high as 75 percent. While still full of side effects, they can allow some people to finish treatment in just six months. they add to the price, however, another $1,000 to $4,000 a week. Drugs that promise to work even better are also being tested.

Those advances are fueling CDC deliberations of whether to change testing guidelines to recommend that anyone born between 1945 and 1965 get a one-time screening. A second CDC-funded study, also published in the Feb. 21 Annals, analyzed models of that option, and concluded it had the potential to save 82,000 lives.

A third study published Monday from Stanford University looked more closely at the price tag, and concluded the new triple-therapy would be cost-effective for people with advanced disease. It’s still cheaper than a transplant costing well over $100,000. But not everyone with hepatitis C will go on to suffer serious liver damage. for those with mild disease, that analysis concluded some gene testing to predict who might really need the costlier triple therapy rather than the older drugs would be a good next step.

It’s not clear how quickly the CDC will settle the boomer-screening question. But doctors at Montefiore Medical Center in New York City have started raising the issue. Montefiore internist Dr. Gary Rogg also says a number of patients have sought testing after seeing hepatitis-awareness ads from the drugs’ manufacturers.

“Now it’s considered a curable disease, that makes all the difference,” says Rogg, who was surprised at some longtime patients’ test results. Even a nurse he knows learned she had it, and the only risk she could recall was a blood transfusion during surgery when she was 10 years old.

According to WebMD, symptoms of hepatitis C include feeling very tired, joint and belly pain, itchy skin, sore muscles, yellowish eyes and skin, and dark urine. since many people with the disease don’t show symptoms, it is common for people to have hepatitis C for 15 years or longer, before it’s diagnosed as chronic hepatitis C.

The CDC has more on hepatitis C.

Nearly three decades have passed since the debate began about a series of symptoms that have come to be known as chronic fatigue syndrome. its cause is still unknown, but over the years, researchers have identified various brain, immune system and energy metabolism irregularities involved. some patients describe the syndrome as feeling like an “unrelenting, unremitting flu.”

Doctors say some treatments can help. Arthur Barsky, a psychiatrist at Brigham and Women’s Hospital in Boston and a professor at Harvard Medical School, says patients need to change how they experience symptoms — typically pain, insomnia and anxiety. when patients adopt a more positive attitude, Barsky points out, it often translates into greater confidence and more energy.

A study published this year in the Lancet found that a form of talk therapy, as well as exercise, offered relief for some patients. Researchers from the United Kingdom looked at cognitive behavior therapy, or CBT.

In the study, over 600 patients with chronic fatigue syndrome were assigned to different treatments. All of them received medical care for symptoms like pain, insomnia or anxiety.

One group got counseled about how to pace activities. Another took part in an exercise program. And a third received the cognitive behavioral talk therapy. the therapy and the exercise group improved the most, reporting less fatigue, insomnia and anxiety.

Barsky says his patients do best when cognitive behavior therapy is also combined with gradually increased exercise. “People need to begin to push themselves in the face of their fatigue, because if you don’t, you become deconditioned and you get caught in a cycle which … makes fatigue worse,” says Barsky.

But he cautions against overdoing it. People should start with mild, gentle exercise like clearing the table, doing the dishes, or taking the dog for a short walk. Then, slowly build up to longer and more frequent walks, he says.

Lucinda Bateman is a doctor at the Fatigue Consultation Clinic in Salt Lake City who specializes in chronic fatigue syndrome.

She’s skeptical about the Lancet study, pointing out that patients improved only moderately, and not much more than those who were counseled about pacing themselves. Bateman suggests her patients pace themselves, and try to do only as many activities as they can manage.

She says some patients get caught in a “push and crash” cycle. when symptoms abate and they feel better, they may go all out, exercising, doing errands and socializing. but soon that level of activity often comes to a crashing end and patients can relapse dramatically, even becoming bedridden for several days or longer.

Bateman takes also issue with CBT’s implication that chronic fatigue syndrome is psychosomatic. we still don’t know what exactly causes the syndrome. And, like most professionals who treat patients, Bateman eagerly awaits the day when science can finally pinpoint its cause.

With additional reporting from Joanne Silberner

30 years ago this month, my son’s autistic symptoms emerged.having lived with autism in the family for almost 3 decades, Individualized Autism Intervention for Young Children: Blending Discrete Trial and Naturalistic Strategies, is quite simply, in my opinion, the best book yet in sorting out what we know and what we can do to alter the course of autism in young children.As an expert senior psychologist and grandparent, Travis Thompson has given us a ground breaking contribution based upon solid theory and emerging research evidence.

From the Brookes Publishing web site: “Discrete trial instruction or naturalistic, incidental teaching: How do you choose which approach to use with young children with autism? now there’s no need to ‘pick a side’—this groundbreaking book helps professionals skillfully blend the best of both behavioral approaches to respond to each child’s individual needs… this guidebook cuts through the chaos of conflicting information and gives readers a logical, child-centered way to plan and implement intervention.”

I am particularly excited about the possibilities for the Autism Intervention Responsiveness Scale, Research Edition, which is included in the book. This scale gives professionals an in-depth guide to creating an autism intervention profile for each child, based on the type and severity of the child’s autism characteristics.By completing the profile, readers can then match individual characteristics and needs with a specially tailored blend of discrete trial and developmentally oriented naturalistic teaching.

On the other hand, I am deeply troubled by budget cuts that threaten services vitally necessary for children with autism and their families.As Thompson notes, “Most evidence indicates that 25-30 hours per week of one-to-one intervention over the first 1-2 years is required to make significant gains in core autism symptoms for children who are responsive to this form of treatment.”(p.41)

The time is now for professionals and families to push back through our organizations and the political process for what children need and deserve to have the best life possible.

Read an interview with Doctor Thompson at brookespublishing.com/autism/authors/thompson.htm

IntroductionBecause concerning the sociable changes, which has brought enhanced number of workingwoman and thus delayed childbearing, there goes on to be a steep rise in your number of busts cancer people in your final few decades. But since the event concerning folks has risen so has raised the modality of treatment options simultaneously since the success rates. Also researchers have devised options by which the cancer may probably be detected in an previously stage also it goes on to be convincingly proved that previously detection and medication bears an improved prognosis compared to later stage.

MythsThere are rather a few myths attached to busts cancer. Some feel that any lump in busts may probably be a busts cancer but to the contrary most of these are benign. Similarly it experienced been a popular belief previously that breast-feeding reduces one’s risk concerning the cancer but which goes on to be now found being untrue. Some say that mammography causes the busts cancer widespread but it’s not true. Similarly there are rather a few other myths, which need being cleared in thoughts concerning the general conglomeration for the proper detection and administration concerning the tumor.

Early detectionBreast cancer may probably be detected in an previously stage if women are taught to self-examine their breast. in case of detection of any busts lump or of any slightest suspicion, mammography have to be completed to rule out any tumor. Mammography may probably be a excellent gadget to identify this sort of cancer.

StatisticsThe event of busts cancer is increasing at an alarming rate. it is mentioned that every 2-3 minutes one special American woman is identified a busts cancer.

CauseAlthough the lead to is not fully understood however it is hypothesized that there are various variables this sort of as genetic and environmental. The environmental variables are enhanced age, obesity, tobacco use and possessing the initial child at past due age.

DiagnosisThe findings that denote a cancer are single, non-tender and service provider to very hard conglomeration with ill-defined margins. This may probably be later confirmed by mammography and biopsy. once the cancer goes on to be identified staging is completed to get out the best medication selection simultaneously since the prognosis.

ManagementThe administration of busts cancer rests basically on two things. The initial is the medication and subsequent is the counseling. The medication can further be split into three: medical, radiation, and surgery. The medical medication consists of drugs this sort of as tamoxifen, which can be definitely an anti estrogen, aromatase inhibitors this sort of as aminoglutethimide and monoclonal antibodies this sort of as trastuzumab. But identical to other drugs they have their own undesirable aspect effects profile. The undesirable aspect effects related to tamoxifen are enhanced vaginal bleeding, endometrial cancer and cataracts. The aromatase inhibitors have the undesirable aspect effects of leg cramps, jaundice and extra weight whilst the monoclonal antibodies may probably lead to sterility or a number of shipping and delivery abnormalities.Generally the radiation and surgery would be the modalities, that are essential for the medication to ward away the comprehensive body concerning the cancerous growth.

CounselingThis is one special on fundamentally the most important elements concerning the medication both just before and once the surgery. The individuals are being taught that this is only another disease, which has medication available, and people can lead a normal life style once that.

Latest researchLatest research is being completed on both the surgery simultaneously since the medicine. For the surgery, surgeons are seeking to get out the best way of surgery creating sure that publish surgery the individuals have minimal disabilities. identical treatments with lower undesirable aspect effects are being researched.

Google is your friend.

yellow skin.eyes………….

While all types your asking about are different from one another they can have a few of the same side effects.
HAV is food borne and resolves on its own- HAV is usually acute- within minutes a person becomes ill. Jaundice,vomitting, diareaha, fever, chills….
HBV- acute can cause the same, chronic can cause many other health related issues.
HCV- may or may not be acute- acute infection tends to resolve on it's own but can be life threatening, most are chronically infected in which it can take years to decades before the symptoms are noticable. there are over 150 extrahepatic diseases associated with HCV- too many to list here, but the main ones are lethargy, depression, brain fog, fibromyalgia, hair loss, thyroid disease, heart palpitations, upper right quadrant pain, low grade (chronic) fever…..

We’ve spent the past few decades preaching about how important it is to stay out of the sun. We’ve understood just how real a risk skin cancer can be and are doing every little thing we can think of to prevent it from happening. we slather on layers and layers of the largest SPF sunscreens that we can buy. we place huge old floppy hats on our heads. we wear long sleeves in addition to pant legs even in the warmest of temps. we try and stick to the shady areas—some folks have even taken to carrying parasols around with them to keep the sun from ever making contact with their skin.

Some people think that perfumes like Michael Kors Perfume will protect their skin from the sun but that is not for certain.

Now we’re discovering that the sun can actually be beneficial! can sunshine actually help you?

I personally avoid the sun by staying indoors and going shopping in malls or other stores looking for Crystal Chandeliers for Sale

A new study has been performed and it shows that people who allow some time in direct sunshine aren’t as likely to get MS as the people who do everything they can to keep out of the sun. the study was originally performed to discover how Vitamin D affects the progression of Multiple Sclerosis. It didn’t take long for them to realize that it is the Vitamin D our bodies produce after exposure to sunlight that is at the center of the issue.

We’ve known for a very long time that the sun’s rays and Vitamin D can impede the way the immune system plays a role in MS. this study, on the other hand, focuses on the affects of sunlight on individuals who are experiencing the very earliest symptoms of the disease. this study is trying to figure out the effects of Vitamin D in addition to the sun’s rays on the precursory symptoms of the disease.

Unfortunately there are not a massive amount of ways to really quantify the hypothesis of the study. the objective of the study is to find out if sunlight can actually prevent the disease. unfortunately, the researchers discovered, the only way to that is to watch people over the course of their lives. this is only way that it may be possible to calculate and fully grasp the levels of Vitamin D that exist in a person’s blood before the precursors of the disease show up. the way it is now, people who get normal exposure to the sun appear to experience fewer symptoms of MS than those who live in colder or darker climates–which isn’t new news.

There is also the very important problem that spending a lot of time in the sunlight greatly increases a person’s chances of developing skin cancer. so, in an attempt to keep one particular illness from setting in, you could be inadvertently causing another. of course, if it gets caught in early stages, skin cancer is very treatable and can even be cured. this isn’t true for MS.

So what should you do: chance skin cancer or risk MS? Your physician may help you figure out whether or not this is an option for you. Your health care provider will look into your current state of health and fitness, your health history and even into your genetics to help you figure out if you even sit at risk for the disease at all. from there your physician will help uou discover the best ways to keep the disease at bay.

Some doctors have said that eating quinoa can help with Multiple Sclerosis symptoms, so I recommend looking at Quinoa Recipes Easy to learn more.

Press Release Source: Pharmaxis, Inc. On Wednesday February 23, 2011, 4:20 pm EST

EXTON, Pa., Feb. 23, 2011 /PRNewswire/ — Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for chronic respiratory and immune disorders, announced today the commercial launch of ARIDOL® (mannitol inhalation powder) Bronchial Challenge Test Kit, the first new bronchial challenge test in more than two decades and the company’s first product launch in the U.S.  ARIDOL is used to assess bronchial hyperresponsiveness in patients six years of age and older who do not have clinically apparent asthma.  ARIDOL should not be used as a stand alone test to assess asthma or as a screening test for asthma, but as part of a physician’s overall assessment of asthma.  ARIDOL can be ordered directly from Pharmaxis and is available to pulmonary function labs and physicians’ offices by calling Pharmaxis Customer Service at 1-888-416-1828.  

“ARIDOL is an important advancement in bronchial challenge testing – the first in 20 years – and a significant addition to the tools available to help in an overall assessment of asthma,” said Stephen Beckman, President, Pharmaxis, Inc.  ”We are excited to provide patients and the medical community with an effective, accurate and reproducible test that can be conducted in the convenience of a pulmonary function lab or physician’s office.”

ARIDOL is a single-use, indirect test that is easy-to-administer, requires minimal preparation time and a 15% reduction in lung function from baseline for a positive test.  ARIDOL was approved by the U.S. Food and Drug Administration (FDA) on October 5, 2010, and demonstrated safety and efficacy in two Phase III clinical trials.

“The ARIDOL Bronchial Challenge Test takes only about 20 minutes to administer for a positive test and requires a 15% reduction in FEV[1].  Previous options may take up to 40 minutes to implement and require a 20% reduction in FEV[1],” said Bradley Chipps, MD, Capital Allergy and Respiratory Disease Center, Sacramento, CA.  “The ARIDOL Bronchial Challenge Test offers health care professionals another tool to help with a disease that is often hard to definitively diagnose.”  

“PHARMAXIS is committed to bringing our therapeutic advances for respiratory and immune diseases to patients throughout the world.  The U.S. launch of ARIDOL highlights this commitment and our focus on helping physicians and patients world-wide affected by respiratory illnesses,” added mr. Beckman.

How ARIDOL Works

The ARIDOL test requires patients to inhale increasing doses of dry powder mannitol from a simple, hand-held device, which causes airways to narrow and contract when airway inflammation is present. the doses are contained in capsules that are administered at one-minute intervals until a positive response is achieved or until all the capsules have been inhaled, indicating a negative result.  A positive response is indicated when there is a 15% reduction in lung function from baseline compared to a 20% fall required by a methacholine challenge test.(1) the lower the dose required to cause bronchoconstriction, the more severe the bronchial hyperresponsiveness.    

Other Bronchial Challenge Tests

Unlike other bronchial challenge tests, ARIDOL is a single-use test that requires less preparation time and eliminates reconstitution, use of a nebulizer to administer, clean-up and sterilization.  A positive ARIDOL test is complete in approximately 20 minutes, compared to an average of 45 minutes for a methacholine test.(2) a methacholine test requires additional equipment to administer and a designated testing room with ventilation.(1) Tests that use exercise to assess bronchial hyperreponsiveness require special equipment and conditions, and may not be appropriate for patients with physical limitations.

Safety/Efficacy Profile

The safety and efficacy of ARIDOL as a bronchial challenge test were verified in two global Phase III clinical trials, which assessed the effectiveness of the ARIDOL bronchial challenge test in non-asthmatic patients with symptoms suggestive of asthma and clinically diagnosed asthmatic patients six years of age and older.  Approved for use in 19 countries, ARIDOL has been used by more than 44,000 patients, and is marketed in Australia, major European countries and Korea.  ARIDOL is included in official international guidelines for the clinical assessment of asthma. Organizations and guidelines endorsing ARIDOL include: the International Olympic Committee Medical Commission’s Independent Panel on Asthma, the U.S. Asthma Management Guidelines, the Global Initiative for Asthma (GINA) Report on Global Strategy for Asthma Management and Prevention, the World Anti-Doping Agency and the Australian Asthma Management Handbook. ARIDOL is the only dry powder bronchial challenge test approved for use in the U.S.

Indication

Mannitol, the active ingredient in ARIDOL, is a sugar alcohol indicated for the assessment of bronchial hyperresponsiveness in patients 6 years of age or older who do not have clinically apparent asthma.  

ARIDOL is not a stand alone test or a screening test for asthma.  Bronchial challenge testing with ARIDOL should be used only as part of a physician’s overall assessment of asthma.

Important Safety Information

WARNING: RISK OF SEVERE BRONCHOSPASM

Mannitol, the active ingredient in ARIDOL, acts as a bronchoconstrictor and may cause severe bronchospasm.  Bronchial challenge testing with ARIDOL is for diagnostic purposes only.  Bronchial challenge testing with ARIDOL should only be conducted by trained professionals under the supervision of a physician familiar with all aspects of the bronchial challenge test and the management of acute bronchospasm. Medications (such as short acting inhaled beta-agonist) and equipment to treat severe bronchospasm must be present in the testing area.  If severe bronchospasm occurs it should be treated immediately by administration of a short acting inhaled beta-agonist. because of the potential for severe bronchoconstriction, bronchial challenge testing with ARIDOL should not be performed in any patient with clinically apparent asthma or very low baseline pulmonary function tests (e.g., FEV[1]